Gossamer Bio Competitors

Gossamer Bio (NASDAQ:GOSS) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are held by institutional investors. 23.3% of Gossamer Bio shares are held by company insiders. Comparatively, 4.3% of Global Blood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Gossamer Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Gossamer Bio and Global Blood Therapeutics, as reported by MarketBeat.

Gossamer Bio presently has a consensus target price of $23.00, indicating a potential upside of 170.91%. Global Blood Therapeutics has a consensus target price of $90.3158, indicating a potential upside of 121.31%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than Global Blood Therapeutics.

Profitability

This table compares Gossamer Bio and Global Blood Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Gossamer Bio and Global Blood Therapeutics' top-line revenue, earnings per share and valuation.

Gossamer Bio has higher earnings, but lower revenue than Global Blood Therapeutics. Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Gossamer Bio beats Global Blood Therapeutics on 8 of the 13 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Earnings & Valuation

This table compares Gossamer Bio and Intra-Cellular Therapies' top-line revenue, earnings per share and valuation.

Intra-Cellular Therapies has higher revenue and earnings than Gossamer Bio. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Gossamer Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are held by institutional investors. Comparatively, 79.1% of Intra-Cellular Therapies shares are held by institutional investors. 23.3% of Gossamer Bio shares are held by company insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Gossamer Bio and Intra-Cellular Therapies, as reported by MarketBeat.

Gossamer Bio presently has a consensus target price of $23.00, indicating a potential upside of 170.91%. Intra-Cellular Therapies has a consensus target price of $47.4286, indicating a potential upside of 51.92%. Given Gossamer Bio's higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than Intra-Cellular Therapies.

Profitability

This table compares Gossamer Bio and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Summary

Intra-Cellular Therapies beats Gossamer Bio on 8 of the 12 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Gossamer Bio (NASDAQ:GOSS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Ligand Pharmaceuticals and Gossamer Bio's gross revenue, earnings per share (EPS) and valuation.

Ligand Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ligand Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are held by institutional investors. 10.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ligand Pharmaceuticals and Gossamer Bio, as provided by MarketBeat.com.

Ligand Pharmaceuticals presently has a consensus price target of $215.60, indicating a potential upside of 43.51%. Gossamer Bio has a consensus price target of $23.00, indicating a potential upside of 170.91%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Ligand Pharmaceuticals.

Profitability

This table compares Ligand Pharmaceuticals and Gossamer Bio's net margins, return on equity and return on assets.

Summary

Ligand Pharmaceuticals beats Gossamer Bio on 7 of the 13 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and Gossamer Bio (NASDAQ:GOSS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Xencor and Gossamer Bio's gross revenue, earnings per share (EPS) and valuation.

Xencor has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Xencor has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are held by institutional investors. 3.7% of Xencor shares are held by insiders. Comparatively, 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Xencor and Gossamer Bio, as provided by MarketBeat.com.

Xencor presently has a consensus price target of $47.1111, indicating a potential upside of 11.48%. Gossamer Bio has a consensus price target of $23.00, indicating a potential upside of 170.91%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Xencor.

Profitability

This table compares Xencor and Gossamer Bio's net margins, return on equity and return on assets.

Summary

Gossamer Bio beats Xencor on 7 of the 13 factors compared between the two stocks.

ALX Oncology (NASDAQ:ALXO) and Gossamer Bio (NASDAQ:GOSS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares ALX Oncology and Gossamer Bio's gross revenue, earnings per share (EPS) and valuation.

Institutional and Insider Ownership

73.5% of ALX Oncology shares are held by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are held by institutional investors. 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for ALX Oncology and Gossamer Bio, as provided by MarketBeat.com.

ALX Oncology presently has a consensus price target of $90.6667, indicating a potential upside of 49.29%. Gossamer Bio has a consensus price target of $23.00, indicating a potential upside of 170.91%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than ALX Oncology.

Profitability

This table compares ALX Oncology and Gossamer Bio's net margins, return on equity and return on assets.

Summary

ALX Oncology beats Gossamer Bio on 4 of the 6 factors compared between the two stocks.

Cryoport (NASDAQ:CYRX) and Gossamer Bio (NASDAQ:GOSS) are both transportation companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Volatility and Risk

Cryoport has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cryoport and Gossamer Bio's gross revenue, earnings per share (EPS) and valuation.

Cryoport has higher revenue and earnings than Gossamer Bio. Cryoport is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cryoport and Gossamer Bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cryoport and Gossamer Bio, as provided by MarketBeat.com.

Cryoport presently has a consensus price target of $72.00, indicating a potential upside of 39.62%. Gossamer Bio has a consensus price target of $23.00, indicating a potential upside of 170.91%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Cryoport.

Institutional and Insider Ownership

88.3% of Cryoport shares are held by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are held by institutional investors. 11.5% of Cryoport shares are held by insiders. Comparatively, 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cryoport beats Gossamer Bio on 7 of the 12 factors compared between the two stocks.